US Broker Ratings

Janux Therapeutics (JANX) Stock Analysis: Unpacking a 251% Potential Upside in Biotech

Janux Therapeutics, Inc. (NASDAQ: JANX) is capturing attention in the biotechnology sector with its innovative approach to cancer treatment and a remarkable potential upside of 251.09%. As a clinical-stage biopharmaceutical..

Dyne Therapeutics (DYN) Stock Analysis: A Promising Biotech with a Staggering 393% Potential Upside

Dyne Therapeutics, Inc. (NASDAQ: DYN), a key player in the biotechnology sector, is capturing the attention of investors with its potential for substantial growth. Based in Waltham, Massachusetts, Dyne is..

Veracyte, Inc. (VCYT) Stock Analysis: Unveiling a 55% Potential Upside in the Thriving Diagnostics Sector

Veracyte, Inc. (NASDAQ: VCYT), a dynamic player in the healthcare sector, is making waves within the diagnostics and research industry. Based in South San Francisco, this innovative company has carved..

Structure Therapeutics Inc. (GPCR): Investor Outlook Reveals a Staggering 307% Potential Upside

Structure Therapeutics Inc. (NASDAQ: GPCR), a pioneering player in the biotechnology sector, is garnering significant attention among investors due to its promising pipeline and the potential for substantial returns. The..

Acadia Healthcare Company, Inc. (ACHC) Stock Analysis: Examining an 83.78% Potential Upside

Investors eyeing opportunities in the healthcare sector may find Acadia Healthcare Company, Inc. (NASDAQ: ACHC) an intriguing prospect, particularly with an eye-catching potential upside of 83.78%. This Tennessee-based company, specializing..

Biohaven Ltd. (BHVN) Stock Analysis: Exploring a 293% Potential Upside

Biohaven Ltd. (NASDAQ: BHVN), a biotechnology firm that has been making waves in the healthcare sector, presents an intriguing opportunity for investors willing to navigate the complexities of the biotech..

Beam Therapeutics Inc. (BEAM) Stock Analysis: Unveiling a 129.75% Potential Upside

Investors eyeing opportunities in the biotechnology sector may want to focus on Beam Therapeutics Inc. (NASDAQ: BEAM), a company that is not only innovating in genetic medicine but also presents..

Adaptive Biotechnologies (ADPT) Stock Analysis: Navigating Growth in Biotech with a Strong Buy Consensus

Adaptive Biotechnologies Corporation (NASDAQ: ADPT) stands as a promising entity within the ever-evolving healthcare sector, specifically in the biotechnology industry. Despite recent market fluctuations, Adaptive Biotechnologies continues to capture investor..

Kiniksa Pharmaceuticals, Ltd. (KNSA) Stock Analysis: Exploring a 35.96% Potential Upside in Biopharma

Kiniksa Pharmaceuticals, Ltd. (NASDAQ: KNSA) has emerged as a compelling focus for investors seeking growth within the healthcare sector, specifically in the realm of biopharmaceuticals. With a market cap of..

PTC Therapeutics, Inc. (PTCT): Analyzing a 30.91% Potential Upside Amid Robust Revenue Growth

Investors in the biotechnology sector may find PTC Therapeutics, Inc. (PTCT) an interesting prospect, given its current market dynamics and promising financial metrics. Established in 1998 and headquartered in Warren,..

Brookdale Senior Living Inc. (BKD) Stock Analysis: Navigating Challenges and Opportunities with a 15% Upside Potential

Brookdale Senior Living Inc. (NYSE: BKD), a prominent player in the healthcare sector, operates senior living communities across the United States. With a market capitalization of $1.57 billion, Brookdale is..

Ardent Health, Inc. (ARDT) Stock Analysis: Exploring a Potential 52.77% Upside

Ardent Health, Inc. (ARDT), a major player in the healthcare sector, has been capturing investor attention with its significant potential upside. Based in Brentwood, Tennessee, Ardent Health operates an extensive..

Liquidia Corporation (LQDA) Stock Analysis: Unpacking a 143% Potential Upside for Investors

Liquidia Corporation (NASDAQ: LQDA) is a name that has been catching the eye of investors in the biotechnology sector, especially given its impressive potential upside of 143.37%. As a biopharmaceutical..

Clover Health Investments, Corp (CLOV) Stock Analysis: Navigating a 62% Potential Upside in the Healthcare Sector

For investors keeping an eye on the healthcare sector, Clover Health Investments, Corp (NASDAQ: CLOV) presents an intriguing opportunity. With a market capitalization of $1.47 billion, this Delaware-based company is..

Immunocore Holdings plc (IMCR) Investor Outlook: Exploring a 91.86% Potential Upside

Immunocore Holdings plc (NASDAQ: IMCR) is positioned at the forefront of biotechnology innovation, with a focus on developing pioneering immunotherapies for cancer and other serious diseases. Headquartered in Abingdon, United..

Tarsus Pharmaceuticals (TARS) Stock Analysis: Unveiling an 85% Upside Potential with Innovative Eye Care Solutions

Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a dynamic player in the biotechnology sector, is making waves with its innovative approach to eye care and infectious disease prevention. Headquartered in Irvine, California,..

Protagonist Therapeutics, Inc. (PTGX) Stock Analysis: A 38% Potential Upside Amidst Strong Buy Ratings

Protagonist Therapeutics, Inc. (NASDAQ: PTGX) is capturing the attention of investors with its ambitious pipeline in the biotech sector, particularly as it navigates the complexities of hematology and immunomodulatory diseases...

Amicus Therapeutics (FOLD): Analyzing a 161% Potential Upside and Strong Buy Consensus

Amicus Therapeutics, Inc. (NASDAQ: FOLD) is positioning itself within the biotechnology sector as a compelling opportunity for investors who are keen on high-growth potential in the healthcare industry. With a..

Enovis Corporation (ENOV) Stock Analysis: Eyeing a 71% Potential Upside with Strong Buy Ratings

Investors looking for opportunities in the healthcare sector might want to focus their attention on Enovis Corporation (NYSE: ENOV), a medical technology company that has caught the eye of analysts..

AtriCure, Inc. (ATRC) Investor Outlook: A Healthcare Innovator with a Promising 58% Upside Potential

AtriCure, Inc. (ATRC) stands as a compelling prospect in the healthcare sector, particularly for investors with a focus on medical instruments and supplies. With its innovative solutions targeting cardiac arrhythmias..

US Broker Ratings

US Broker Ratings

FTSE 100

Funds